Wechselwirkungen · Mirapexin
MIRAPEXIN 0.26 mg prolonged-release tablets MIRAPEXIN 0.52 mg prolonged-release tablets MIRAPEXIN 1.05 mg prolonged-release tablets MIRAPEXIN 1.57 mg prolonged-release tablets MIRAPEXIN 2.1 mg prolonged-release tablets MIRAPEXIN 2.62 mg prolonged-release tablets MIRAPEXIN 3.15 mg prolonged-release tablets · Abschnitt 4.5 · PDF-Seite 21
HOS-086679 · Präparat HOS-083333
Plasma protein binding Pramipexole is bound to plasma proteins to a very low (< 20%) extent, and little biotransformation is seen in man. Therefore, interactions with other medicinal products affecting plasma protein binding or elimination by biotransformation are unlikely. As anticholinergics are mainly eliminated by biotransformation, the potential for an interaction is limited, although an interaction with anticholinergics has not been investigated. There is no pharmacokinetic interaction with selegiline and levodopa.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): pramipexole (HOS-086613) selegiline (HOS-086575) levodopa (HOS-086559)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-29T09:14:00Z · SHA-256 10b100c75ddc71f5dd2ebff9e8c7467440f96455ec4517ce8521647f7acf11e0 · Passage d719103534b954d0244caaf578422124a1e4d812d4280fc876bccf495db13bfc · Zeichen 0–526 im Abschnitt